Celecoxib-induced deep-vein thrombosis [4]

Annals of Pharmacotherapy

Volumn 39, Issue 6, 2005, Pages 1138-

  Chan, Agnes L F ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; ENOXAPARIN; INDOMETACIN; WARFARIN;

ADULT; CASE REPORT; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; GASTROCNEMIUS MUSCLE; GOUT; HUMAN; LEG PAIN; LEG SWELLING; LETTER; LOW DRUG DOSE; MALE; POPLITEAL VEIN; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRASOUND;

ANTICOAGULANTS; CYCLOOXYGENASE INHIBITORS; ENOXAPARIN; GOUT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; PYRAZOLES; RISK FACTORS; SULFONAMIDES; VENOUS THROMBOSIS; WARFARIN;

EID: 18844406802     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E603     Document Type: Letter

References (5)

1. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001;175:214-7.
2. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002;39:521-2.
3. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum 2000;43:1891-6.
4. Mukherjee D, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:329-45.